Riskpilot← Back to searchSign inGet full accessXboXLab AB
ABActiveOrg 5569453136Svampgatan 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20134 employees
Revenue 2024
SEK 31,9M
+18% vs 2023
EBITDA margin
8.9%
+109% vs 2023
Equity ratio
70.1%
Financial strength
Net profit 2024
SEK 2,2M
+142% vs 2023
| Revenue | SEK 31,9M | +18% |
| EBITDA | SEK 2,8M | +109% |
| Net profit | SEK 2,2M | +142% |
| Total assets | SEK 14,1M | +12% |
| Equity | SEK 9,9M | +14% |
| Employees | 4 | — |
Legal name
XboXLab AB
Org number
5569453136
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 oktober 2013
Share capital
SEK 92 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva marknadsföring, försäljning och distribution, nationellt och internationellt, av laboratorieprodukter, diagnostiska produkter, farmacia, läkemedel och medicinteknisk utrustning, samt vidare tillhandahålla tjänster inom detta område, ävensom idka därmed förenlig verksamhet.
Address
Svampgatan 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 10 039 | 12 240 | 36 415 | 19 403 | 23 263 | 27 123 | 31 937 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | — | −155 | −34 | 921 | 853 | 10 263 | 2 591 | 1 846 | 1 362 | 2 841 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −38 | −140 | −140 | −167 | −290 |
| EBIT | 0 | −155 | −34 | 921 | 853 | 10 225 | 2 451 | 1 706 | 1 195 | 2 551 |
| Net financials | — | — | — | — | — | −16 | −2 | −177 | 78 | 39 |
| Profit before tax | 0 | −155 | −34 | 730 | 639 | 10 209 | 2 449 | 1 529 | 1 110 | 2 727 |
| Tax | −0 | −0 | −0 | −134 | −139 | −2 190 | −507 | −354 | −218 | −567 |
| Net profit | 0 | −155 | −34 | 596 | 500 | 8 019 | 1 942 | 1 175 | 892 | 2 160 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 122 | 270 | 924 | 2 207 | 3 250 | 14 109 | 13 516 | 12 419 | 12 671 | 14 143 |
| Equity | 28 | 153 | 319 | 916 | 935 | 8 704 | 8 646 | 8 821 | 8 713 | 9 916 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 94 | 117 | 605 | 1 101 | 1 909 | 5 000 | 4 464 | 3 193 | 3 390 | 3 796 |
| Total debt | 94 | 117 | 605 | 1 101 | 1 909 | 5 000 | 4 464 | 3 193 | 3 390 | 3 796 |
EBITDA margin
8.9%
This company
15.8%
Market median
-44% vs market
20152024
Equity ratio
70.1%
This company
38.2%
Market median
+84% vs market
20152024
Return on equity
21.8%
This company
18.4%
Market median
+18% vs market
20152024
Net profit margin
6.8%
This company
8.1%
Market median
-16% vs market
20152024
Asset turnover
2.26×
This company
1.12×
Market median
+102% vs market
20152024
Debt / equity
0.43×
This company
0.62×
Market median
+31% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AJ | Audit | 2022 | — | — |
UP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2024 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
XboXLab AB (this company)
Xboxlab ASXBOXLAB OYXboxlab OyXBOXLAB ASBoard members of XboXLab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Jerker Stenqvist | Audit | 0 companies |
| Ulf Peter Blom | Chief Executive Officer | 0 companies |
| Karianne Nyrud Jansen | Deputy Board Member | 0 companies |
| Ingrid Ann-Mari Blom | Deputy Board Member | 0 companies |
| Lisa Anna Elisabet Gustafsson | Board of Directors | 0 companies |
| Anna Maria Almén | Deputy Board Member | 0 companies |
| Christer Karl Uno Lidén | Board of Directors | 0 companies |
| Lennart Sture Gustafsson | Deputy Board Member | 0 companies |
| Karl Niclas Fundin | Deputy Board Member | 0 companies |
| Henning Jansen | Board of Directors | 0 companies |
| Niclas Olof Fundin | Chairman | 0 companies |
| Irma Viola Lidén | Deputy Board Member | 0 companies |